Abstract
10x Genomics / Chromium Single Cell Gene Expression Flex
hromium Single Cell Gene Expression Flex empowers your research in remarkable new ways, enabling you to take scRNA-seq further than it's ever gone before. This advanced chemistry provides our most sensitive whole transcriptome profiling with the ultimate flexibility to meet your experimental needs every step of the way.
Q2 Solutions / Flow Cytometry Services
In an effort to continuously provide industry-leading innovative laboratory testing solutions and cutting-edge technologies to drug developers and patients, Q2 Solutions® has invested heavily to provide next generation spectral flow cytometry systems in our laboratories around the globe covering North America, Europe, Asia Pacific and China, plus a partner laboratory in South Africa, through a multi-year collaboration with Cytek™ Biosciences. Integrated scientific expertise and the exceptional capabilities of Cytek 5 Laser Aurora instrument enable us to deliver flow cytometry panels perfectly designed to fit a specific clinical indication and drug mode of action.
GenomOncology / Insights and Analytics
GenomOncology's precision oncology solutions strengthen insights and analytics and enable institutions to dive deeper into patient data sets to result in data-driven insights designed to improve overall cancer care. The solutions can analyze molecular, clinical, demographic, and treatment data in one, comprehensive view to inform insights and decisions.
Centogene / CENTOGENE NEW CentoGenome®
Serving as a first-line test, CENTOGENE's NEW CentoGenome is the most comprehensive commercially available Whole Genome Sequencing (WGS) test on the market for both rare and neurodegenerative disorders—covering almost all disease-causing variants, including most known repeat expansions associated with neurological diseases, in a single assay1. NEW CentoGenome also detects Copy Number Variations (CNVs) associated with Spinal Muscular Atrophy (SMA), as well as disease-causing variants associated with Gaucher Disease (GD) and susceptibility to GBA1-related Parkinson's Disease (PD), with the highest levels of sensitivity.
